Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Cincinnati
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects enrolled in the trial must meet all of the following criteria.
Confirmed COVID-19 pneumonia
Hypoxia as defined by room air oxygen saturation less than 92% or supplemental oxygen requirement
Presence of at least one additional biomarker that has been shown to predict poor prognosis: a) serum ferritin ≥500ug/l, b) LDH ≥250U/L, c) d-dimer ≥1ug/L, or d) lymphopenia as defined by absolute lymphocyte count \<1,000/uL
Age ≥ 18 years
Completed informed consent
You may not be if
Known allergy or hypersensitivity to sirolimus
Inability or refusal to provide informed consent
Advanced respiratory support (high flow oxygen ≥ 15 L/min, CPAP, non-invasive or invasive mechanical ventilation)
Active enrollment in other interventional clinical drug trials. Co-enrollment in observational studies and biorepositories is allowed.
Pregnant women
Breast feeding
On chronic immunosuppression for other medical conditions such as rheumatological disorders, inflammatory bowel disease, or in patients with organ transplants. A list of these medications is provided in Section 12.3.4
Any clinically significant medical disease which in the opinion of the investigator precludes the patient from enrolling in the trial, including (but not limited to):
* History of liver cirrhosis
* End stage renal disease or need for renal replacement therapy
* Decompensated heart failure
* Known active tuberculosis or history of incompletely treated tuberculosis
* Uncontrolled systemic bacterial or fungal infections
* Active viral infection other than COVID-19
Clareo Health | Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia
